By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
The parathyroid hormone (PTH) form teriparatide, marketed under the trade name Forteo, is made up of the first 34 amino acids (N-terminus), which are the hormone’s bioactive part.
It is a powerful anabolic (bone-formation-promoting) drug used to treat some types of osteoporosis. Sometimes it is used illegally to quicken fracture healing.
Because teriparatide activates osteoblasts more than osteoclasts when used intermittently, there is an overall increase in bone mass. Teriparatide is chemically equivalent to a part of the human parathyroid hormone.
It is successful at promoting bone growth and lowering the risk of fragility fractures (e.g., an 8% increase in bone density in the spine after a year). Teriparatide only improved bone mineral density (BMD) during the first 18 months of usage, according to research.
There should be no more than 2 years of teriparatide use. Even though repeat administration has been utilized in hypophosphatasia, where bisphosphonates are contraindicated, where bisphosphonates are contraindicated, another drug such as a bisphosphonate or denosumab should be given after 2 years in cases of osteoporosis.
Teriparatide significantly reduces the risk of hip fracture, however, it had no effect on the risk of arm or wrist fracture. Patients with a higher risk of osteosarcoma shouldn’t be given teriparatide.
This includes people who have Paget’s disease of the bones, unexplained increases in blood alkaline phosphate, open epiphyses, or a history of skeletal radiation therapy.
It was discovered that it might be connected to the development of osteosarcoma in test subjects after more than two years of use in animal studies and one case report involving humans.
Teriparatide side effects include headache, nausea, vertigo, and limb discomfort. The potential risk of osteosarcoma from teriparatide has only been studied in rats and has not yet been verified in people.
This might be a result of the fact that rats, unlike humans, experience lifelong bone growth. The rat experiments revealed malignancies that developed after the injections started and were discovered to be on the ends of the bones.
Only two incidences of osteosarcoma were recorded after the drug’s nine years on the market. The FDA deemed this danger to be “very rare” (1 in 100,000 people)[9] and it is only slightly more common in the population over 60. (0.4 in 100,000).
The Global teriparatide market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Livogiva has been introduced by Theramex for the first time to patients in Europe. The first country in the EU to offer the treatment in Germany, with France, Italy, and Spain following soon after.
The sole bone anabolic medication for osteoporosis, teriparatide, is now available as Livogiva, a novel formulation that is easier for patients who are at high risk of fractures to take because it comes pre-filled in a pen.
In Europe, osteoporosis is still frequently misdiagnosed and poorly managed, which leads to a lot of fractures. In people over 50, one in three women and one in five men will get a fragility fracture.
1 The most frequent fractures, which have a crippling effect on everyday activities and quality of life, are hip, spinal, and wrist fractures.
